冠状动脉鼻减小剂在耐火性心痛和慢性全闭症患者中的有效性
Maayan Konigstein1, Alice Moroni2, Stefan Verheye2
1Division of Cardiology, Tel Aviv Sourasky Medical Center, affiliated with the Tel Aviv University School of Medicine, Tel Aviv, Israel. Maayan.konigstein@gmail.com.
概括
冠状动脉缩剂 (CSR) 植入有效地缓解冠状动脉慢性全闭症 (CTO) 患者的心痛. 这种治疗改善了CTO和非CTO患者的症状和生活质量.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 慢性冠状动脉完全封闭 (CTO) 经常导致耐火性心痛,并降低生活质量.
- 冠状动脉鼻减小器 (CSR) 植入为耐火性心痛提供了一种安全有效的治疗方法.
研究的目的:
- 评估CSR植入在诊断为CTO的患者中缓解心痛症状的临床有效性.
- 为了比较CSR植入的CTO和没有CTO的患者之间的临床结果.
主要方法:
- 在2011年至2023年期间,一组262名患有耐火性心痛且没有再血管化的患者接受了CSR植入物.
- 胸痛的严重程度,身体能力 (6分钟步行测试) 和生活质量 (SAQ) 在基线,植入后6个月和1年被评估.
- 在有和没有CTO的患者之间比较了结局.
主要成果:
- 一半的患者 (131/262) 患有CTO. 总体而言,77%的人至少提高了一个加拿大心血管学会 (CCS) 课程,42%的人在一年内提高了两个或更多的等级.
- 6分钟的步行测试距离显著增加,简单形式36健康调查 (SAQ) 的所有5个领域都显示出改善 (p < 0.001).
- 在CTO和非CTO组之间,心痛和生活质量的改善是可比的,非CTO患者的6MWT改善趋势更大.
结论:
- 对于患有耐火性心痛的患者来说,CSR植入提供了类似的好处,无论原因是CTO还是非CTO病变.
- 需要进一步的随机前性研究来确定这些患者的最佳治疗策略.
相关概念视频
01:26Angina IV: Management
22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
676
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:27Angina II: Classification
38
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
38
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505